Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Growth 2025-2031

Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Growth 2025-2031

The global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market size is predicted to grow from US$ 2197 million in 2025 to US$ 2855 million in 2031; it is expected to grow at a CAGR of 4.5% from 2025 to 2031.

Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families. In 1983, Coates et al. found that patients receiving chemotherapy ranked nausea and vomiting as the first and second most severe side effects, respectively. Up to 20% of patients receiving highly emetogenic agents in this era postponed, or even refused, potentially curative treatments. Since the 1990s, several novel classes of antiemetics have been developed and commercialized, becoming a nearly universal standard in chemotherapy regimens, and helping to better manage these symptoms in a large portion of patients. Efficient mediation of these unpleasant and sometimes crippling symptoms results in increased quality of life for the patient, and better overall health of the patient, and, due to better patient tolerance, more effective treatment cycles.

Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs key players include Merck, Eisai, Mundipharma, etc. Global top three manufacturers hold a share over 50%.

North America is the largest market, with a share about 50%, followed by China, and Europe both have a share about 35 percent.

In terms of product, 5-HT3 Inhibitors is the largest segment, with a share over 60%. And in terms of application, the largest application is Moderately Emetogenic Chemotherapy, followed by Highly Emetogenic Chemotherapy, Low Emetogenic Chemotherapy, etc.

LP Information, Inc. (LPI) ' newest research report, the “Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Industry Forecast” looks at past sales and reviews total world Chemotherapy Induced Nausea and Vomiting (CINV) Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Chemotherapy Induced Nausea and Vomiting (CINV) Drugs sales for 2025 through 2031. With Chemotherapy Induced Nausea and Vomiting (CINV) Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Chemotherapy Induced Nausea and Vomiting (CINV) Drugs industry.

This Insight Report provides a comprehensive analysis of the global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Chemotherapy Induced Nausea and Vomiting (CINV) Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Chemotherapy Induced Nausea and Vomiting (CINV) Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs.

This report presents a comprehensive overview, market shares, and growth opportunities of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
5-HT3 Inhibitors
NK1 Inhibitors
Other

Segmentation by Application:
Highly Emetogenic Chemotherapy
Moderately Emetogenic Chemotherapy
Low Emetogenic Chemotherapy
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Merck
Eisai
Mundipharma
Qilu Pharma
Teva
Novartis
Heron Therapeutics
Roche
Mylan
Tesaro

Key Questions Addressed in this Report

What is the 10-year outlook for the global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market?

What factors are driving Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market opportunities vary by end market size?

How does Chemotherapy Induced Nausea and Vomiting (CINV) Drugs break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.